Other
Influenza vaccine, injection
PBAC's latest decision on Influenza vaccine, injection: Recommended with restriction (2009). Considered for Universal vaccination against influenza of all persons aged 65 years and older.
PBAC outcome
Recommended with restriction
National Immunisation Program
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2009 → 2009
Eligible population persons aged 65 years and older
Therapy area Other Line of therapy Not applicable Evidence base RCT Primary endpoint seroprotection rates, geometric mean titres (GMT) Key trials GID16, GID17 Comparator 15 microgram intramuscular (IM) influenza vaccines (Vaxigrip) Economic model Cost-minimisation Budget impact $-10000000 Eligible patients/year 2,000,000 ICER note Cost-minimisation analysis; no ICER calculated as economic evaluation was based on cost-minimisation rather than cost-effectiveness Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.